|
RFXAP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62458935193399E-12 |
| Normal-vs-Stage2 |
1.63780100592703E-12 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.027600E-01 |
| Stage1-vs-Stage3 |
6.525900E-02 |
| Stage1-vs-Stage4 |
2.977900E-03 |
| Stage2-vs-Stage3 |
1.147970E-01 |
| Stage2-vs-Stage4 |
6.835200E-03 |
| Stage3-vs-Stage4 |
1.450580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.44990019990132E-10 |
| Normal-vs-Asian |
1.75504055732745E-12 |
| Caucasian-vs-AfricanAmerican |
6.737600E-01 |
| Caucasian-vs-Asian |
1.528370E-01 |
| AfricanAmerican-vs-Asian |
6.116600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62458935193399E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
2.225600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
2.54710000002767E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.268800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.053400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.645400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.028000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.040800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.639800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.342180E-02 |
| Classical-VS-Follicular |
9.245800E-02 |
| Classical-VS-Other |
6.821400E-01 |
| Classical-VS-Normal |
1.11022302462516E-16 |
| Tall-VS-Follicular |
1.324370E-03 |
| Tall-VS-Other |
3.122200E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.499400E-01 |
| Follicular-VS-Normal |
4.68514116391816E-14 |
| Other-VS-Normal |
2.433200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.282100E-02 |
|
|
